Advisors Capital Management LLC lifted its position in Stryker Corporation (NYSE: SYK) by 2.9% during the undefined quarter, according to the company in its most recent filing with the Securities and
Stryker (SYK) delivered strong Q3 2025 results, raising full-year guidance on robust organic growth across both MedSurg & Neurotechnology and Orthopaedics segments. SYK achieved double-digit organic s
Stryker (SYK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Stryker: Striking Again

04:30am, Monday, 03'rd Nov 2025
Stryker continues to deliver strong organic growth, having posted organic growth rates of around 10% for a long period of time now. The $4.9 billion Inari Medical acquisition announced this year will
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Stryker Corporation ( SYK ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Kevin Lobo - Chairman, CEO & President Jason Beach - Vice President of Finance & Investor Relations
Stryker on Thursday raised the lower end of its full-year profit forecast after beating estimates for third-quarter earnings, banking on strong demand for its medical and surgical devices.
Stryker (SYK) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $2.87 per share a year ago.
The medical products maker now expects sales to grow 9.8% to 10.2% in the full year.
Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025:
Beyond analysts' top-and-bottom-line estimates for Stryker (SYK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e
Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.
There are two types of Halloween people: those who like jump scares and those who don't. But even if you're a fan of haunted hayrides and movies like The Conjuring, you probably don't want to ever get
MCO, SYK and CBRE stand out as wide moat stocks with strong growth forecasts and strategic expansions to boost portfolio resilience.
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE